FLT3 and acute myeloid leukemia: Sorafenib for relapsed FLT3‐ITD‐positive AML presenting as leukemia cutis has rarely been described.2 This case highlights the need to consider leukemia cutis in the differential diagnosis of a rash early post‐alloSCT and the rapidity of the response that can be achieved with sorafenib.